MX2022009379A - Metodos de tratamiento con anticuerpos anti interleucina 17a/17f (il-17a/f). - Google Patents
Metodos de tratamiento con anticuerpos anti interleucina 17a/17f (il-17a/f).Info
- Publication number
- MX2022009379A MX2022009379A MX2022009379A MX2022009379A MX2022009379A MX 2022009379 A MX2022009379 A MX 2022009379A MX 2022009379 A MX2022009379 A MX 2022009379A MX 2022009379 A MX2022009379 A MX 2022009379A MX 2022009379 A MX2022009379 A MX 2022009379A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- antibodies
- methods
- dermatological
- psoriasis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención se refiere a usos terapéuticos de moléculas de anticuerpo que tienen especificidad por determinantes antigénicos de IL-17A e IL-17F en el tratamiento de enfermedades dermatológicas y reumatológicas, tales como psoriasis, artritis psoriásica y espondiloartritis axial.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562246989P | 2015-10-27 | 2015-10-27 | |
US201662303230P | 2016-03-03 | 2016-03-03 | |
US201662346826P | 2016-06-07 | 2016-06-07 | |
US201662405546P | 2016-10-07 | 2016-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022009379A true MX2022009379A (es) | 2022-09-07 |
Family
ID=57223670
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018005031A MX2018005031A (es) | 2015-10-27 | 2016-10-26 | Metodos de tratamiento con anticuerpos anti interleucina 17a/17f (il-17a/f). |
MX2022009380A MX2022009380A (es) | 2015-10-27 | 2018-04-24 | Metodos de tratamiento con anticuerpos anti interleucina 17a/17f (il-17a/f). |
MX2023004315A MX2023004315A (es) | 2015-10-27 | 2018-04-24 | Anticuerpo neutralizante que se une a il-17a humana y a il-17f humana para usarse en el tratamiento de artritis. |
MX2022009379A MX2022009379A (es) | 2015-10-27 | 2018-04-24 | Metodos de tratamiento con anticuerpos anti interleucina 17a/17f (il-17a/f). |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018005031A MX2018005031A (es) | 2015-10-27 | 2016-10-26 | Metodos de tratamiento con anticuerpos anti interleucina 17a/17f (il-17a/f). |
MX2022009380A MX2022009380A (es) | 2015-10-27 | 2018-04-24 | Metodos de tratamiento con anticuerpos anti interleucina 17a/17f (il-17a/f). |
MX2023004315A MX2023004315A (es) | 2015-10-27 | 2018-04-24 | Anticuerpo neutralizante que se une a il-17a humana y a il-17f humana para usarse en el tratamiento de artritis. |
Country Status (15)
Country | Link |
---|---|
US (3) | US11492396B2 (es) |
EP (1) | EP3368570A1 (es) |
JP (4) | JP6931648B2 (es) |
KR (1) | KR20180067676A (es) |
CN (2) | CN108350068A (es) |
AU (2) | AU2016347471B2 (es) |
BR (1) | BR112018008075A2 (es) |
CA (1) | CA3001260A1 (es) |
CL (3) | CL2018001135A1 (es) |
CO (1) | CO2018004493A2 (es) |
IL (1) | IL258515A (es) |
MX (4) | MX2018005031A (es) |
RU (1) | RU2754683C2 (es) |
SG (2) | SG11201802887PA (es) |
WO (1) | WO2017072183A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200277369A1 (en) * | 2017-11-20 | 2020-09-03 | Novartis Ag | Method of treating hidradentitis suppurativa with il-17 antagonists |
GB201719447D0 (en) * | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
WO2021050563A1 (en) * | 2019-09-09 | 2021-03-18 | The Rockefeller University | Antibody treatment for lesional tissue of hidradenitis suppurativa |
EP4289863A1 (en) * | 2020-12-17 | 2023-12-13 | Shanghai Huaota Biopharmaceutical Co., Ltd. | Bispecific antibody targeting il-17a and il-36r and application thereof |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
EP1892296A1 (en) | 1988-09-02 | 2008-02-27 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
DK0744958T3 (da) | 1994-01-31 | 2003-10-20 | Univ Boston | Polyklonale antistofbiblioteker |
FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
ES2374068T3 (es) | 2002-12-03 | 2012-02-13 | Ucb Pharma, S.A. | Ensayo para identificar células productoras de anticuerpos. |
GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
PT1644412E (pt) | 2003-07-01 | 2015-12-23 | Ucb Biopharma Sprl | Fragmentos de anticorpos fab modificados |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
ES2347840T3 (es) | 2006-02-10 | 2010-11-04 | Zymogenetics, Inc. | Il-17rcx4 soluble y procedimiento de utilizacion en la inflamacion. |
EP1996622A2 (en) * | 2006-03-10 | 2008-12-03 | Zymogenetics, Inc. | Antibodies that bind both il-17a and il-17f and methods of using the same |
TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
GB0620729D0 (en) * | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
CL2008000883A1 (es) * | 2007-03-28 | 2008-10-03 | Wyeth6 3 | Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a |
CN101842387B (zh) | 2007-09-26 | 2014-05-07 | Ucb医药有限公司 | 双特异性抗体融合物 |
GB0807413D0 (en) * | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
EP2288382B1 (en) | 2008-05-05 | 2018-08-29 | NovImmune SA | Anti- il-17a/il-17f cross-reactive antibodies and methods of use thereof |
US8790642B2 (en) * | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
WO2010035012A1 (en) | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
RU2394575C1 (ru) * | 2009-04-13 | 2010-07-20 | Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "УрНИИДВиИ Росмедтехнологий") | Способ лечения псориаза |
JP6053517B2 (ja) | 2009-05-05 | 2016-12-27 | ノヴィミュンヌ エスア | 抗il−17f抗体およびそれらの使用法 |
ES2667258T3 (es) | 2009-09-10 | 2018-05-10 | Ucb Biopharma Sprl | Anticuerpos multivalentes |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
CN103154031A (zh) * | 2010-10-08 | 2013-06-12 | 诺华有限公司 | 利用il-17拮抗剂治疗牛皮癣的方法 |
ME02734B (me) * | 2011-01-14 | 2017-10-20 | Ucb Biopharma Sprl | Antitelo koje vezuje il-17a i il-17f |
UA117218C2 (uk) * | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
CA2856252A1 (en) | 2011-11-21 | 2013-05-30 | Novartis Ag | Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non-response alleles |
CN104244979A (zh) | 2012-04-20 | 2014-12-24 | 诺华股份有限公司 | 使用il-17拮抗剂治疗强直性脊柱炎的方法 |
GB201213571D0 (en) | 2012-07-31 | 2012-09-12 | Univ Leuven Kath | Growth factor cocktail to enhnce osteogenic differentiayion of mesenchymal |
PL2953969T3 (pl) * | 2013-02-08 | 2020-02-28 | Novartis Ag | Przeciwciała anty-il-17a i ich zastosowanie w leczeniu zaburzeń autoimmunologicznych i zapalnych |
WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
CA2960754A1 (en) | 2014-09-10 | 2016-03-17 | Novartis Ag | Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients |
RU2020124276A (ru) | 2015-10-19 | 2021-08-03 | Новартис Аг | Способы лечения нерентгенографического аксиального спондилоартрита, используя антагонисты интерлейкина-17 (il-17) |
GB201522391D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibody molecules |
RU2680011C2 (ru) | 2016-04-29 | 2019-02-14 | Закрытое Акционерное Общество "Биокад" | Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы |
-
2016
- 2016-10-26 KR KR1020187014392A patent/KR20180067676A/ko not_active Application Discontinuation
- 2016-10-26 MX MX2018005031A patent/MX2018005031A/es unknown
- 2016-10-26 EP EP16790313.7A patent/EP3368570A1/en active Pending
- 2016-10-26 US US15/771,310 patent/US11492396B2/en active Active
- 2016-10-26 RU RU2018118029A patent/RU2754683C2/ru active
- 2016-10-26 SG SG11201802887PA patent/SG11201802887PA/en unknown
- 2016-10-26 WO PCT/EP2016/075821 patent/WO2017072183A1/en active Application Filing
- 2016-10-26 CN CN201680062741.XA patent/CN108350068A/zh active Pending
- 2016-10-26 AU AU2016347471A patent/AU2016347471B2/en active Active
- 2016-10-26 CA CA3001260A patent/CA3001260A1/en active Pending
- 2016-10-26 SG SG10202112586WA patent/SG10202112586WA/en unknown
- 2016-10-26 CN CN202211252125.4A patent/CN116059350A/zh active Pending
- 2016-10-26 BR BR112018008075A patent/BR112018008075A2/pt not_active Application Discontinuation
- 2016-10-26 JP JP2018521530A patent/JP6931648B2/ja active Active
-
2018
- 2018-04-05 IL IL258515A patent/IL258515A/en unknown
- 2018-04-24 MX MX2022009380A patent/MX2022009380A/es unknown
- 2018-04-24 MX MX2023004315A patent/MX2023004315A/es unknown
- 2018-04-24 MX MX2022009379A patent/MX2022009379A/es unknown
- 2018-04-26 CO CONC2018/0004493A patent/CO2018004493A2/es unknown
- 2018-04-27 CL CL2018001135A patent/CL2018001135A1/es unknown
-
2021
- 2021-04-27 JP JP2021074962A patent/JP6931750B2/ja active Active
- 2021-06-01 JP JP2021092630A patent/JP7176044B2/ja active Active
- 2021-10-26 CL CL2021002815A patent/CL2021002815A1/es unknown
- 2021-10-26 CL CL2021002816A patent/CL2021002816A1/es unknown
-
2022
- 2022-10-11 US US18/045,597 patent/US20230279093A1/en active Pending
- 2022-10-11 US US18/045,623 patent/US20230287100A1/en active Pending
- 2022-11-09 JP JP2022179423A patent/JP2023025019A/ja active Pending
-
2023
- 2023-10-27 AU AU2023255037A patent/AU2023255037A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022006573A (es) | Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias. | |
MX2022009379A (es) | Metodos de tratamiento con anticuerpos anti interleucina 17a/17f (il-17a/f). | |
EA201300819A1 (ru) | Молекулы антител, которые связываются с il-17a и il-17f | |
PE20170704A1 (es) | Agente terapeutico que induce citotoxicidad | |
CO2018006667A2 (es) | Moléculas de anticuerpo multiespecífico que tienen especificidad para tnf-alfa, il-17a e il-17f | |
BR112016010513A2 (pt) | anticorpos anti-il-17, método de produção e uso dos mesmos | |
EA201290360A1 (ru) | Гуманизированные антитела против il-22ra человека | |
PH12021550521A1 (en) | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof | |
UA117466C2 (uk) | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 | |
MY184189A (en) | Methods of treating nail and scalp psoriasis | |
CY1125041T1 (el) | Αντισωματα anti-il-22r | |
EA201891594A1 (ru) | Антитела к il-17c | |
MX2018012410A (es) | Metodos para tratar enfermedades inflamatorias. | |
EA201890983A1 (ru) | Способы лечения с использованием анти-il-17a/f антител | |
MX2018007221A (es) | Moleculas de anticuerpos que se unen al factor de necrosis tumoral alfa (tnf alfa). | |
CL2023002975A1 (es) | Anticuerpo multiespecífico con especificidad de unión para il-13 e il-17 humanas | |
MX2022007117A (es) | Anticuerpo con especificidad de enlace para la il-13 humana. | |
AR106507A1 (es) | Métodos para el tratamiento de enfermedades dermatológicas y reumatoideas |